Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Swiss Life Asset Management Ltd

Swiss Life Asset Management Ltd reduced its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,521 shares of the biopharmaceutical company’s stock after selling 2,268 shares during the quarter. Swiss Life Asset Management Ltd’s holdings in Alnylam Pharmaceuticals were worth $9,814,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALNY. Root Financial Partners LLC acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $25,000. Salomon & Ludwin LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $27,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $29,000. Ameriflex Group Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $32,000. Finally, ORG Partners LLC raised its position in shares of Alnylam Pharmaceuticals by 70.2% in the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 33 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,598 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $523,584.70. Following the sale, the executive vice president directly owned 36,606 shares in the company, valued at $11,993,955.90. The trade was a 4.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Pushkal Garg sold 1,775 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $319.74, for a total value of $567,538.50. Following the transaction, the executive vice president owned 23,406 shares of the company’s stock, valued at approximately $7,483,834.44. This trade represents a 7.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 53,923 shares of company stock worth $18,072,087 over the last quarter. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $312.17 on Friday. The company has a fifty day simple moving average of $335.41 and a 200 day simple moving average of $405.36. The firm has a market cap of $41.40 billion, a price-to-earnings ratio of 182.56 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). The firm had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business’s quarterly revenue was up 84.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.65) EPS. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Freedom Capital raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. Wells Fargo & Company lowered their target price on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 20th. Morgan Stanley cut their price target on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a report on Friday, January 30th. Wall Street Zen lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Truist Financial decreased their price objective on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $468.84.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.